Scientists at Washington University School of Medicine in St. Louis have developed a vaccine that targets the SARS-CoV-2 virus, can be given in one dose via the nose, and is effective in preventing infection in mice susceptible to the novel coronavirus.
The investigators—Michael S. Diamond, MD, PhD the Herbert S. Gasser Professor of Medicine and a professor of molecular microbiology, and of pathology and immunology and David T. Curiel, MD, PhD, the Distinguished Professor of Radiation Oncology—are testing the vaccine in nonhuman primates and humans to see if it is safe and effective in preventing COVID-19 infection. Their findings first appeared in the journal Cell.
Read more about this innovative approach, and why nasal delivery is considered promising in the fight against COVID-19, at the School of Medicine’s website.
Comments and respectful dialogue are encouraged, but content will be moderated. Please, no personal attacks, obscenity or profanity, selling of commercial products, or endorsements of political candidates or positions. We reserve the right to remove any inappropriate comments. We also cannot address individual medical concerns or provide medical advice in this forum.